Terms of Service

Service Description and Eligibility

Terms governing the miCheckup service.

Please read these terms carefully before purchasing or using miCheckup.

Effective Date: January 1, 2025

These Terms of Service ("Terms") govern your use of the miCheckup microRNA multi-cancer early detection (MCED) test and the micheckup.com website (collectively, the "Service") provided by miRoncol Health Inc. ("miRoncol Health," "we," "us," "our"), a corporation incorporated under the laws of Canada with its principal office in Ottawa, Ontario.

By purchasing, accessing, or using the Service, you agree to be bound by these Terms. If you do not agree, do not use the Service.

Service description: miCheckup is a microRNA-based multi-cancer early detection (MCED) test built on a microRNA multi-disease screening (MMDS) platform. The Service includes blood sample collection at a partner collection centre, microRNA profiling analysis, results delivery through a secure platform, physician review, and (if applicable) whole-body MRI and structured follow-up.

Eligibility: The Service is available to adults aged 18 and older located in Canada. You must provide accurate personal and health information. You must be capable of providing informed consent. The Service is designed for asymptomatic screening — if you are experiencing symptoms that may indicate cancer, seek medical attention immediately.

Not a diagnostic test: miCheckup is an early detection screening tool designed to identify suspected cancer signals that may warrant further investigation. It is not a diagnostic test. A positive result does not confirm cancer. A negative result does not rule out cancer. All results should be discussed with a qualified healthcare provider.

Limitations, Liability, and Governing Law

Limitations of liability and dispute resolution.

Important legal limitations governing the miCheckup service.

Limitation of liability: miCheckup is provided "as is" as a screening service based on current scientific research. miRoncol Health does not guarantee the detection of any specific cancer type or stage. To the maximum extent permitted by applicable law, miRoncol Health's total liability for any claim arising from the Service shall not exceed the amount paid by you for the Service.

No medical advice: Content on micheckup.com is provided for informational purposes only and does not constitute medical advice. The information provided through the Service, including screening results, is not a substitute for professional medical advice, diagnosis, or treatment.

Intellectual property: All content, technology, algorithms, trade marks, and intellectual property associated with miCheckup and micheckup.com are owned by miRoncol Health Inc. and protected by Canadian and international intellectual property laws.

Modification of terms: We reserve the right to modify these Terms at any time. Material changes will be communicated via email or through the Service. Continued use of the Service after notification constitutes acceptance of the modified Terms.

Governing law: These Terms are governed by the laws of the Province of Ontario and the federal laws of Canada applicable therein. Any disputes shall be resolved in the courts of the Province of Ontario, Canada.

Cancellation and refunds: Cancellation and refund policies are described on our Pricing page. Once a blood sample has been collected and processing has begun, refunds may not be available.

Contact: For questions about these Terms, contact us at legal@mironcol.com or by mail at miRoncol Health Inc., Ottawa, Ontario, Canada.

Important Safety Information

miCheckup is intended for adults at or above the age of majority in their province (18 or older in most provinces; 19 or older in British Columbia, New Brunswick, Newfoundland and Labrador, Nova Scotia, Northwest Territories, Nunavut, and Yukon). miCheckup is a multi-cancer early detection (MCED) test — an early warning test intended to identify a suspected cancer signal associated with multiple solid tumor cancers from a single blood draw. miCheckup does not detect all cancers and should be used in addition to routine cancer screening tests recommended by your healthcare provider.

Use of miCheckup is not recommended in individuals who are pregnant or planning pregnancy, under the age of majority in their province, currently undergoing active cancer treatment, or currently experiencing symptoms that may indicate cancer. If you are experiencing symptoms, please consult your physician directly.

Results should be interpreted by a healthcare provider in the context of your medical history, clinical signs, and symptoms. All miCheckup results are reviewed with you by a physician. A result of "no suspected cancer signal identified" does not rule out cancer. A result of "suspected cancer signal identified" is not a diagnosis — it requires confirmatory diagnostic evaluation by medically established procedures, which is why a whole-body MRI and physician follow-up are included in your miCheckup test.

If a suspected cancer signal is identified but cancer is not confirmed with further testing, it could mean that cancer is not present, or that testing was insufficient to detect cancer — including due to the cancer being located in an area or of a type not well represented in the miCheckup signal. False positive results (a suspected cancer signal identified when cancer is not present) and false negative results (no suspected cancer signal identified when cancer is present) do occur.

miCheckup is a complement to, not a replacement for, standard cancer screening programs. Continue all recommended screening — including mammography, Pap/HPV testing, and colorectal screening (FIT or colonoscopy) — as directed by your healthcare provider. Cancer diagnosis in Canada always requires a tissue biopsy confirmed by a pathologist. If a suspected cancer signal is identified, imaging and clinical workup by your healthcare team will determine the actual status. Many findings turn out to be benign after further investigation.

Laboratory/Test Information

miCheckup is a multi-cancer early detection (MCED) Laboratory-Developed Test (LDT), performed at an accredited Canadian medical laboratory certified by the Institute for Quality Management in Healthcare (IQMH). In Canada, LDTs are regulated as a clinical laboratory service under provincial and territorial laboratory oversight. Your blood sample is collected, processed, and analyzed entirely within Canada.

The miCheckup microRNA analysis is based on peer-reviewed research published in Scientific Reports (Nature Portfolio, 2024) and Cancers (MDPI, 2022), validated on thousands of peer-reviewed blood samples, with ongoing validation through the Ontario Health Study using 4,000+ Canadian blood samples.

Published validation shows greater than 99% specificity and greater than 90% sensitivity for the majority of cancer types in the current miCheckup panel of multiple solid tumor cancers. Performance may vary by cancer type and individual factors. For a detailed breakdown of sensitivity and specificity by cancer type, and the complete list of cancers currently in the miCheckup panel, visit The Science.

All personal health data is stored in Canada and handled in accordance with the Personal Information Protection and Electronic Documents Act (PIPEDA) and applicable provincial health privacy legislation, including the Personal Health Information Protection Act (PHIPA) in Ontario.

miCheckup is currently available in Ontario, expanding across Canada. For the full safety, regulatory, and performance disclosure, see Important Information.

References

Government of Canada. "Consumer protection laws in Canada." canada.ca

Terms governing the miCheckup service.

Limitations of liability and dispute resolution.

Questions about our terms?

Important Safety Information

Laboratory/Test Information

References